Tokyo, Oct. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059331) titled 'Special drug use-results survey on BALVERSA' on Oct. 8.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - unresectable urothelial carcinoma with FGFR3 gene mutations or fusion genes that has progressed after cancer chemotherapy
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the occurrence of eye disorders (excluding retinal detachment and corneal disorder) and severe skin disorders (excluding hand and foot syndrome) in patients with radically unresectable urothelial carcinoma with FGFR3 gen...